Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $297.17, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG.
Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company selling instruments, reagents, and consumables in 36+ countries. Approximately 60% of net sales came from international locations, with Europe as the largest... Read more
Sell if holding. At $297.17, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Bio-Rad Laboratories, Inc.
Latest news
- NEWS Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Up - Here's Why - MarketBeat — MarketBeat positive
- NEWS Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year - Yahoo Finance — Yahoo Finance positive
- NEWS Are Options Traders Betting on a Big Move in Nuvation Bio Stock? - TradingView — TradingView positive
- NEWS Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com — Investing.com negative
- NEWS Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus — GuruFocus positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational locations60%10-K Item 1: 'We generated approximately 40% of our consolidated net sales for the year ended December 31, 2025 from the U.S. and approximately 60% from our international locations'
- HIGHcounterpartySartorius AG10-K Item 1A: 'Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income (loss) and other financial statements'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWAt April 21, 2026 annual meeting, stockholders approved amended Bio-Rad 2017 Incentive Award Plan adding 335,000 shares (to 5,535,000 total) and extending expiration to March 18, 2036.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $297.17, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $277.63. Score 5.0/10, moderate confidence.
Take-profit target: $313.46 (+5.5% upside). Prior stop was $277.63. Stop-loss: $277.63.
Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG; Analyst target reached - limited upside remaining.
Bio-Rad Laboratories, Inc. trades at a P/E of 48.6 (forward 30.0). TrendMatrix value score: 5.1/10. Verdict: Sell.
10 analysts cover BIO with a consensus score of 3.5/5. Average price target: $297.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company...
Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company selling instruments, reagents, and consumables in 36+ countries. Approximately 60% of net sales came from international locations, with Europe as the largest international region; the company also holds a $5.67B fair-value equity stake in Sartorius AG that materially impacts financial results.